tldrdailynews.com logo

Cytokinetics' Heart Drug Gains FDA Approval, Boosting Its Market Edge

1 min read
Source: statnews.com
Cytokinetics' Heart Drug Gains FDA Approval, Boosting Its Market Edge
Photo: statnews.com
TL;DR

Cytokinetics received FDA approval for its first drug, Myqorzo, to treat obstructive hypertrophic cardiomyopathy, ending a 27-year R&D drought for the company. The drug will compete with a similar medication from Bristol Myers Squibb and is expected to launch in late January.

Topics:businesshealthcare#cytokinetics#fda-approval#healthcare#heart-drug#hypertrophic-cardiomyopathy#myqorzo
Share this article
  1. Cytokinetics heart drug wins FDA approval, the biotech’s first  statnews.com
  2. Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms  Cytokinetics
  3. US FDA approves Cytokinetics' heart disease drug  Reuters
  4. Cytokinetics Has Doubled Since May. Does It Still Have Steam?  Investor's Business Daily
  5. FDA approves Cytokinetics’ heart drug, giving it an edge over BMS rival  Endpoints News

Want the full story? Read the original reporting

Read on statnews.com